open access

Vol 10, Supp. A (2019)
Case report
Published online: 2019-04-26
Get Citation

The problem of leukocytosis control in a patient with primary myelofibrosis treated with ruxolitinib

Marta Sobas1, Anna Czyż1, Krzysztof Zduniak2, Monika Biedroń1, Tomasz Wróbel1
DOI: 10.5603/Hem.2019.0006
Affiliations
  1. Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku, Samodzielny Publiczny Szpital Kliniczny, Uniwersytet Medyczny we Wrocławiu
  2. Katedra i Zakład Patomorfologii, Uniwersytet Medyczny we Wrocławiu, Wrocław, Poland

open access

Vol 10, Supp. A (2019)
CASE REPORTS
Published online: 2019-04-26

Abstract

Ruxolitynib — JAK1/JAK2 inhibitor — registrated for patients with myelofibrosis (MF) IPSS (International Prognostic Scoring System) intermediate-2 or high, with splenomegaly and general symptomatology. Moreover, ruxolitinib is used to reduce splenomegaly and general symptomatology in patients with MF who are candidates for allogeneic hematopoietic stem cells transplantation (allo- -HSCT). Anemia, thrombocytopenia and occasionally leukopenia with neutropenia are observed as a main side effects of ruxolitinib. Moreover, there are problems related to cytokine storm caused by treatment discontinuation. Here we report the patient with MF and important leucocytosis, in whom splenomegaly and general symptoms were reduced due to ruxolitinib. However, ruxolitinib in monotherapy did not reduce the leukocyte count, so the the combined therapy with ruxolitinib plus hydroxycarbamide was initiated. As the result of the treatment, reduction of number of leukocytes was observed, meanwhile the level of hemoglobin was stable and platelets count drop slightly. Thereafter, the patient proceeded to allo-HSCT. So far, there are two cases of patients treated with ruxolitinib plus hydroxycarbamid published in the literature. We think, that all cases treated in that way, should be reporteds, as we can establish the safety of this drug combination.

Abstract

Ruxolitynib — JAK1/JAK2 inhibitor — registrated for patients with myelofibrosis (MF) IPSS (International Prognostic Scoring System) intermediate-2 or high, with splenomegaly and general symptomatology. Moreover, ruxolitinib is used to reduce splenomegaly and general symptomatology in patients with MF who are candidates for allogeneic hematopoietic stem cells transplantation (allo- -HSCT). Anemia, thrombocytopenia and occasionally leukopenia with neutropenia are observed as a main side effects of ruxolitinib. Moreover, there are problems related to cytokine storm caused by treatment discontinuation. Here we report the patient with MF and important leucocytosis, in whom splenomegaly and general symptoms were reduced due to ruxolitinib. However, ruxolitinib in monotherapy did not reduce the leukocyte count, so the the combined therapy with ruxolitinib plus hydroxycarbamide was initiated. As the result of the treatment, reduction of number of leukocytes was observed, meanwhile the level of hemoglobin was stable and platelets count drop slightly. Thereafter, the patient proceeded to allo-HSCT. So far, there are two cases of patients treated with ruxolitinib plus hydroxycarbamid published in the literature. We think, that all cases treated in that way, should be reporteds, as we can establish the safety of this drug combination.
Get Citation

Keywords

mielofibrosis, ruxolitinib, hydroxyurea, leucocytosis, safety

About this article
Title

The problem of leukocytosis control in a patient with primary myelofibrosis treated with ruxolitinib

Journal

Hematology in Clinical Practice

Issue

Vol 10, Supp. A (2019)

Article type

Case report

Pages

1-7

Published online

2019-04-26

DOI

10.5603/Hem.2019.0006

Keywords

mielofibrosis
ruxolitinib
hydroxyurea
leucocytosis
safety

Authors

Marta Sobas
Anna Czyż
Krzysztof Zduniak
Monika Biedroń
Tomasz Wróbel

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.